In a bid to bolster its neuroscience pipeline, Eli Lilly has entered in a research collaboration agreement to discover, develop and commercialise new therapies for the treatment of amyotrophic lateral sclerosis (ALS). The deal, which is worth US$718 M, gives Lilly access to artificial intelligence-driven technology platform which will be used in the discovery of new therapies for ALS.